Adaptation of a human gut epithelial model in relation to the assessment of clinical pharmacokinetic parameters for selected tyrosine kinase inhibitors by Richard J Honeywel et al.
doi: 10.5599/admet.3.1.169 51 
ADMET & DMPK 3(1) (2015) 51-67; doi: 10.5599/admet.3.1.169 
 
Open Access : ISSN : 1848-7718  
http://www.pub.iapchem.org/ojs/index.php/admet/index   
Original scientific paper 
Adaptation of a human gut epithelial model in relation to the 
assessment of clinical pharmacokinetic parameters for 
selected tyrosine kinase inhibitors 
Richard J Honeywell, Christien Fatmawati, Marita Buddha; Sarina Hitzerd, Ietje 
Kathman and Godefridus J. Peters* 
Dept. of Medical Oncology, VU University Medical Center, PO Box 7057, 1007 MB  Amsterdam, The Netherlands 
 
*
Corresponding author, E-mail: gj.peters@vumc.nl, tel: +3120 444 2633, fax: +3120 444 3844,  
Received: February 19, 2015; Revised: March 24, 2015; Published: March 31, 2015  
 
Abstract 
The absorption, efflux and transport properties of two of the most commonly used tyrosine kinase 
inhibitors (TKIs), Erlotinib (E) and Gefitinib (G) were investigated using an adapted workable 
methodology of a 3-day Caco-2 cell monolayer transwell system, a standard model to test drug 
permeability and uptake of orally administered compounds. Monolayer integrity was tested using 
trans-epithelial electrical resistance (TEER) measurements, while drug concentrations were 
determined with a validated LC-MS/ MS technique. Addition of 5 % bovine serum albumin (BSA) 
maintained drug concentrations at ± 20 µM through the avoidance of chelate formation, 
(nevertheless, a reduced accumulative mass transport of the protein bound drug was observed). 
Investigation with Ko143 (a specific blocker of ABCG2) or NaN3 (a metabolic inhibitor) indicated an 
interplay between active transport and to a less degree passive diffusion for gefitinib. However, for 
erlotinib results indicate a more dominant passive diffusion supported by one or more active 
transport mechanisms. The use of Ko143 suggests that ABCG2 is partially involved with accumulation 
of both erlotinib and gefitinib in the intestinal cell. This adapted methodology is well suited for 
absorption, efflux and transport studies and may be extended to investigate the dominant 
mechanism involved in the transport of TKIs. 
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Introduction 
In recent years, approaches to treatment of various different oncological disorders have been 
directed towards the application of a series of small molecules referred to as tyrosine kinase inhibitors 
(TKIs). This loosely related family of molecules specifically target the tyrosine kinase domain of growth 
factor receptors in the cellular membrane or cytosol which play an important role in the control of cell 
growth and replication [1-4]. Two of the most commonly used TKIs are erlotinib (non-small cell lung 
cancer (NSCLC), pancreatic cancer (PC)) and gefitinib (NSCLC) [5]. Erlotinib and gefitinib both show 
similarity in their basic structure with a central pyrimidine core, an adenosine triphosphate (ATP) 
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binding side chain and a basic side chain (Figure 1). Both gefitinib and erlotinib specifically target 
epidermal growth factor receptor (EGFR) [6]. 
  
Figure 1. The physical and chemical properties for Gefitinib (Ge) and Erlotinib (Er). Log P is estimated by 
Viswanadhan’s fragmentation [7]. 
 
TKIs represent an orally self-administered treatment that can be handled on an outpatient basis. 
Oral administration has a lot of beneficial aspects such as ease of use and suitability for long term 
treatment. However, resistance to these molecules can develop over time. This may be mediated by 
one of the multidrug resistance (MDR) proteins which form a group of active efflux pumps of the ATP 
binding-cassette (ABC) drug transporters; the pumps may catalyze the efflux of TKIs out of the 
enterocyte cells [8-10]. There are seven subfamilies of ABC efflux transporter (ABCA – ABCG) based on 
their domain structure [11]. Drug interaction with the efflux transporter as a substrate or an inhibitor 
depends on the concentration of drugs, for example ABCG2 may transport substrates like erlotinib and 
gefitinib at low concentrations (0.1 – 1 μM) [11], but shows inhibitory reaction with these drugs at 
higher concentrations [12-15]. The ABCG2 might transport substrates in the same way as ABCB1 that 
expels the drugs out of the cell or only translocate them inside of the cell [15], for which both 
conditions are lessening the effectiveness of treatment. 
In addition to MDR, barriers to oral chemotherapy are the intestinal drug permeability uptake 
through epithelial cells of the inner intestinal wall, metabolism in the liver and enzymatic degradation 
in the intestinal tract [16]. The overall prediction of efficacy of an oral based treatment is possible by 
using an appropriate model system in vitro [17]. An ideal model system for intestinal absorption is 
based on the growth of a cellular monolayer and the careful comparison of the drug transport across 
this barrier. This system is referred to as a transwell system and consists of a donor, receiver and 
cellular compartment. Figure 2 illustrates the schematic diagram of a compartmental model and 
working model of a transwell system. Transport processes can occur with both a unidirectional and/or 
a bi-directional mechanism of either active transport by a receptor based protein system or by passive 
diffusion along a concentration gradient [18]. Active transport requires energy (ATP dependent) and 
can be against a concentration gradient, it plays a major role in the uptake of hydrophilic compounds 
into the cell and in the efflux of drug out of the cell. Passive diffusion from higher to lower 
concentration is ATP independent and occurs through lateral diffusion, transcellular or paracellular 
pathway [18]. 
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Figure 2. Schematic diagram of Caco-2 cell monolayer and drug transport processes in the transwell system. 
Apical side represents the luminal side of the enterocyte and basolateral side represents the blood circulation. 
The dashed arrow describes drug uptake from the apical to the basolateral side where the apical side serves as 
donor compartment and basolateral side serves as receiver compartment. Single headed arrows in the transport 
processes between compartments describe unidirectional processes while the double-headed arrows describe 
bidirectional processes. Drug transport between cellular compartments involves bidirectional processes. 
 
A widely used model system consisting of a Caco-2 cell monolayer, which is a polarized cell line 
derived from human epithelial colorectal adenocarcinoma cells [19]. When cultured as a monolayer 
(in vitro), this cell line demonstrates the same phenotype, morphology and functions as enterocytes of 
the small intestine [20-23]. Since this cell line expresses the same enzymes and transport proteins that 
mediate drug uptake or efflux in the intestine, it is possible to determine significant correlation 
between permeability of compounds under in vivo conditions [23]. The transwell system has become 
the standard model to test the drug permeability and uptake of orally administered compounds [17]. 
Caco-2 cell monolayers enable investigation into the absorption of drugs, the passive and the active 
transport systems of its transport processes across a barrier directly comparable to the human 
system. 
A disadvantage of this model system is the standard 21 day protocol for the formation of the Caco-
2 monolayer [23]. An alternative 3-day culture system offers a more convenient and productive 
alternative that has been demonstrated to provide comparable results to the standard system [24]. 
 We optimized this model to investigate the absorption, efflux and transport properties of two 
TKIs, namely erlotinib and gefitinib, utilizing LC-MSMS sensitivity to reliably measure the individual 
compound levels [25]. 
Experimental  
Materials 
Erlotinib and gefitinib were purchased from LC Laboratories (Woburn, MA, USA). All general 
reagents were purchased from Sigma (Zwijndrecht, The Netherlands). Ko143 was a kind gift of 
Professor GJ Koomen, University of Amsterdam, The Netherlands. Fetal bovine serum (FBS) was 
purchased from PAA Laboratories GmbH (Pasching, Austria) while the bovine serum albumin (BSA) 
fraction V was purchased from Roche Diagnostics (Mannheim, Germany). Roswell Park Memorial 
Institute (RPMI) 640 medium, trypsin-­EDTA, penicillin, streptomycin (10000 U/ml) and 1 M Hepes 
Buffer (in 0.85 %  NaCl) were purchased from Lonza Benelux BV (Breda, NL). Hank’s balanced salt 
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solution (HBSS) containing CaCl2 and MgCl2 as the transport medium for drug transporting cross cell 
monolayer was purchased from Invitrogen (Breda, The Netherlands). The growth medium (Dulbecco’s 
Modified Eagle Medium (DMEM) based), differentiation medium (a serum free medium containing 
butyric acid) to induce fully differentiation to enterocytes and supplemental medium to maintain the 
cells under serum free condition specific for Caco-2 cell monolayer were purchased from BD Biocoat™ 
(Breda, The Netherlands). High purity erlotinib and gefitinib was obtained from LC-Laboratories 
(Massachusetts, USA). Analytical grade solvents like acetonitrile, methanol and isopropanol were 
purchased from Biosolve BV (Valkenwaard, NL). Bio­Rad Protein Assay was purchased from Bio-­Rad 
Laboratories GmbH (München, DE). MilliQ water was supplied via a MilliQ water purification system 
(Millipore, NL). All other reagents were of an analytical grade unless stated and sourced locally. 
Equipment 
The BIOCOAT® HTS Caco­2 Assay System and BD FalconTM 24-well Multiwell Plates were 
purchased from Becton Dickinson BV (Breda, NL). Breathe-Easier microplate sealing film was 
purchased from Diversified Biotech BV (Ulvenhout, NL). The microplate reader was provided by Tecan 
Benelux BVBA (Giessen, NL) and SPECTRA Fluor software (XFluor4 version V 4.50) was used. The Trans 
Epithelial Electrical Resistance (TEER) meter (Millicell® – ERS) was provided by Millipore (Amsterdam, 
NL). The liquid chromatography coupled to mass spectrometry (LC-MS/MS) analyses were performed 
using a Dionex Ultimate 3000 system coupled with an API 3000 mass spectrometer. For this system 
the following software was used; Analyst version 1.5.2 from Applied Biosciences, in combination with 
Dionex, Chromeleon LC modules version 6.8, controlled by Dionex Mass link (DMS) version 2.10 . 
Cell Culture 
The transwell system was developed using the wild type Caco-2 cell line (passage 15 – 25) after 
defrost. Cells were cultured routinely in DMEM containing 4.5 g/ liter glucose and L-glutamine 
supplemented with 10 % FBS and 20 mM of HEPES at standard conditions of 37 °C, 5 % CO2 and 100 % 
humidity. Confluent cells were detached using trypsin EDTA and past twice weekly. Cells were seeded 
at a density 6.6 x 105 cells/ cm2 on a Biocoat 24 well transwell plate (1 µm pore size, 0.31 cm2 surface 
area) pre-wetted with 50 µl of growth medium for 5 – 10 minutes prior to seeding. Plates were 
incubated for 20 – 24 hours with growth medium and then for 44 – 48 hours with differentiation 
medium at standard conditions. Both media were enriched with the supplemental medium (1:1000) 
and with 1 % Penicillin/ Streptomycin while maintaining conditions for growth and differentiation as 
specified by the supplier’s protocol. In addition, the plate was covered with Breathe-Easier cell culture 
foil during incubation period to maintain identical environmental conditions for each well. 
Monolayer Integrity – Transepithelial Electrical Resistance (TEER) 
The development of a good integrity monolayer on semi-permeable filters in the transwell system 
is the initial crucial step prior to any drug uptake and/or transport investigation. Transepithelial 
electrical resistance (TEER) measures the ion permeability through the paracellular pathways and is 
used to determine the “intactness” of each grown monolayer. The benefit of TEER is the speed of 
measurements and the accuracy with which the integrity can be measured.   
To this end transport medium was prepared on the day of treatment by buffering HBSS; pH 7.4 
with 25 mM HEPES and 0.35 g/ litre NaHCO3 [23] then adjusted to pH 7.4 with NaOH. Within the 
transwell plate the differentiation medium was replaced with prepared transport medium (apical - 
300 µl and basolateral - 1 ml) and incubated for 15 minutes with gentle agitation (100 rpm) under 
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standard conditions. TEER was determined using the potential difference between two electrodes 
suspended across the monolayer. Measurement between each well was performed after a short 
washing period of the electrodes in ethanol then transport medium. The resistance measured for each 
monolayer before and after the experiment was adjusted by a blank resistance determined from the 
wells without a monolayer and multiplied by 0.31 cm
2
 (the area of effective membrane diameter). A 
cut off value of 600 – 1600 Ω cm
2
 was used for determining monolayer integrity according to 
specifications obtained from BD BioCoat™. 
Transport Studies 
Transport studies of 20 µM Erlotinib and Gefitinib were performed in the direction apical to 
basolateral (A - B) and in the direction basolateral to apical (B - A). Inhibition of cellular pump function 
was investigated with either 200 nM Ko143 or 1 mM NaN3. Wells were pre-incubated under standard 
conditions for 20 minutes with 400 nM Ko143 or 1 hour with 3 mM NaN3; gentle agitation (100 rpm) 
was applied during the incubation. All drugs were dissolved in transport medium either containing 5 % 
BSA or containing 5 % BSA + 1 mM NaN3 and added to the donor compartment either apical (300 µl) 
or basolateral (1 ml). The initial concentration of the drug was verified from a 20 µl sample taken 
immediately from the donor compartment after drug administration (t = 0). Subsequently, samples 
(50 µl) were taken from each receiver compartment at the time points 15, 30, 60, 90, 120 and 180 
minutes after drug administration. Following each sampling, the volume of sample taken was replaced 
by the same amount of pre-warmed transport medium. The plate was incubated with gentle agitation 
(100 rpm) at standard conditions between each time point. A final sample of 20 µl was taken from the 
donor compartment after 180 minutes. All samples were placed in pre-labelled tubes, stored on ice 
temporarily during the experiment, snap frozen in liquid nitrogen and stored at -80°C until required 
for analysis. After the final sample time point, cells were washed, trypsinized and harvested; the 
pellets were stored at -80 °C until analysis. 
Liquid Chromatography Analysis 
Extractions for chromatographic analysis of standard and samples were all performed on ice as 
detailed. Analysis of samples taken from the donor and receiver compartments as well as the 
prepared cell pellet was performed by LC-MS/ MS techniques. A simple extraction procedure of 
protein precipitation with acetonitrile was performed for each sample and standard preparation as 
reported previously [25]. LC-MS/ MS analysis was performed with a mobile phase consisting of 
acetonitrile, ammonium acetate (20 mM, pH 7.8) and methanol in the ratio of 66.1:24.5:8.3 %  (v/v) 
with 1 %  isopropyl alcohol added as a chromatographic modifier. Chromatographic separation was 
obtained with a Phenomenex prodigy ODS3 column, 3 µm particle sizes, 100 x 2.00 mm (Phenomenex, 
the Netherlands) at a flow rate of 0.2 ml/ minute. All mobile phases were filtered through a 0.2 µm 
Sartorius membrane filter and degassed for 5 minutes under vacuum with sonication.  
Calculation and Statistics 
The permeability coefficient (Papp) represents a measure for the efficiency of transport and was 
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where ∆Q/ ∆t = the rate of increase in drug concentration (accumulative mass transport) in the 
receiver compartment over time (µM/ second), V = volume in the receiver compartment (ml), C0 = 
the initial concentration of drug in the donor compartment (µM), and A = the membrane surface area 
(cm
2
).   








   
Efflux ratios > 1 indicate that drug efflux occurred during the drug transport experiment. The Papp 
ratios are shown as a mean value of three or more measurements ± SEM. Statistical significance was 
determined using a simple Student’s t-test where a p value of < 0.05 was considered significant. 
Results and Discussion 
Methodology Development 
Drug concentration 
To establish a baseline for the proposed transwell transport studies a plate with no prepared 
monolayer was used as a control system. Either erlotinib or gefitinib was placed in the donor 
compartment dissolved in medium. However, control samples taken from the donor compartment 
medium revealed a curious decrease in concentration over time (Table 1). A drug concentration of 20 
µM had been added to the donor compartment, but the actual concentration measured after the 3 hr 
experiment was repeatedly lower than expected, gefitinib by 1.5 fold and erlotinib by 2 to 3 fold. The 
observed decrease was not related to the added stock solution since analysis of this gave the correct 
concentration and the amount transported to the receiver compartment was negligible compared to 
the change observed. TKIs of this type are extremely insoluble in aqueous solutions (HBSS buffer in 
this instance) and are known systemically to be 90 – 100 % bound to plasma protein [6]. Therefore it 
was investigated whether the drug solubility was the issue behind the decreasing drug concentrations. 
Analysis of drug concentration in the prepared medium immediately after dilution showed 
concentrations in the 20-21 µM range.  
 
Table 1. Apical concentrations of Erlotinib and Gefitinib (without BSA) after 0 








(µM ± SEM) 
Apical  
3 hour 
(µM ± SEM) 
Erlotinib 20 10.1 ± 0.2 7.1 ± 0.03 
Gefitinib 20 19.2 ± 0.3 14.8 ± 0.7 
 
However, the same solution demonstrated a similar decrease in concentration after 24 hours as 
compared to the 3 hours post experimental sample. The lowering of the TKIs’ concentration was 
investigated by LC-MS/ MS and complexes were observed that could be linked to the chelation of the 
TKIs to the metal ions in the HBSS buffer, Mg2+ and Ca2+ (data not shown). It was determined that 
ADMET & DMPK 3(1) (2015) 51-67 Adaptation of human gut epithelial model 
doi: 10.5599/admet.3.1.169 57 
these compounds will form chelation complexes in the ratios 2:3 for gefitinib and 1:2 for erlotinib, 
these complexes were not broken up during sample preparation and hence the relative concentration 
of drug appears to decrease over time. To prevent chelation, bovine serum albumin (BSA) was added 
to the transport medium at a concentration of 5 % v/v, subsequently measured concentrations after 3 
hours at 37 °C matched the expected concentration of 20 µM for both Erlotinib and Gefitinib (Figure 
3). In addition, it was also determined that the addition of NaN3 or Ko143 to the transport medium did 
not significantly affect the initial and post donor concentrations of either Erlotinib or Gefitinib when 















































Figure 3. Comparison of the concentration determined for prepared 20 µM solutions of Erlotinib or Gefitinib 
in HBSS buffer after 3 hours at 37 °C with and without 5 %  bovine serum album – (BSA). Addition of BSA 
prevented chelation of both Erlotinib and Gefitinib during the course of the 3 hour experimental procedure 
which was not affected by the addition of Ko143 or Sodium Azide. (µM ± SEM of n=16). 
 
Using these conditions the transport over the blank transwell system (no-monolayer) was 
determined. Samples were taken from the receiver compartment on the same time schedule as the 
proposed experimental procedure. Figure 4 shows the graphical representation of the transport 
characteristics of gefitinib under these conditions. Linear transport characteristics are observed with 
both conditions. Post experiment each donor well was drained and washed three times with fresh 
medium. Using a 1 % DMSO solution of ethanol each used compartment was washed and the effluent 
collected. Analysis of the effluent revealed no evidence Gefitinib remaining on the compartment 
surfaces (data not shown). 
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Transwell monolayer reproducibility 
Cells were prepared as a monolayer using a 3-day culture protocol by Yamashita et al [24] supplied 
as a commercial kit by Becton Dickinson BV (the Netherlands). Monolayer integrity was determined by 
TEER measurements prior to and after 3 hours post addition of the drugs. Values such as 260 ± 65 Ω 
cm
2
 [23] and 300 – 600 Ω cm
2
 have been quoted in literature as being a specification cut-off. [26] 
However, under 300 Ω cm
2
 we observed transport characteristics that were similar to a well with no 
monolayer while above 1600 Ω cm
2
 transport characteristics were highly different in regards to mass 
transported. Hence, the specifications for monolayer integrity was set in the range 600 – 1600 Ω cm
2
, 
this was in agreement with the technical information as supplied by Becton Dickinson.  
Initial TEER values revealed a problem to the formation of consistent monolayers linked to the well 
position within each 24 well plate. Wells closer to the sides of the plate often had TEER values 
indicating an incomplete monolayer, whereas more centrally placed wells were within the approved 
specification, indicating a complete monolayer. It was observed that Caco-2 monolayers were highly 
sensitive to minor fluctuations in temperature, humidity and CO2 content; these fluctuations affected 
individual wells depending on the plate orientation and position within the incubator. To regulate the 
environment within each well a breathable membrane seal was applied, this was sufficient for 
reproducible monolayers across the entire plate to be formed within the 3-day growth period.  
An additional problem was observed with the TEER measurements post experiment, here TEER 
values of 300 Ω cm
2
 or lower were observed indicating loss of monolayer integrity at an unknown 
stage during the experimental procedure. Post experiment each well was carefully washed free of 
drug containing medium with the intention of recovering as many cells as possible for accumulation 
analysis. Additionally this washing step was included since it was unknown whether the added drugs 
to the medium would affect the TEER measurements. However, this washing step disrupted the 
monolayer significantly giving the “out of specification” TEER values. Avoiding the final washing stage 
TEER values demonstrated good integrity over the course of the 3 hour experiment for all the wells 
tested both with and without the addition of the drugs under investigation (table 2) Recovered cells 
were subsequently washed during the recovery process. 
 
Table 2. Good monolayer integrity was indicated by TEER value in the range of 
600 – 1600 Ω cm
2
. Each box represents one well in the transwell plate. The 
grey boxes indicate the wells without monolayer (blank). The TEER 
measurements were performed before and after the experiment of transport 
studies. 
 1 2 3 4 5 6 
A 1016.8 1674.0 1246.2 737.8 62.0 62.0 
B 1109.8 905.2 1271.0 713.0 651.0 688.2 
C 883.5 1153.2 1023.0 1147.0 744.0 775.0 
D 1240.0 1550.0 1209.0 1581.0 1612.0 781.2 
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Referenced literature recommended 500 µl as the sampling volume from the receiver 
compartment, replacing volume taken at each time point with fresh drug free medium at the correct 
temperature [23]. In initial plates post experiment TEER values revealed that in many cases monolayer 
integrity was compromised with values both lower and higher than specification. Subsequent analysis 
of the receiver compartment samples showed abrupt changes in mass transport, increasing for TEER 
values under specification but decreasing for TEER values above specification. These abrupt changes 
were not observed in wells with consistent TEER values prior to and post drug addition. The problem 
was associated with the mixing of the media in the receiver compartment after sampling. It was 
concluded that hydrostatic pressure from pipette aspiration could either induce stress on the 
monolayer causing a break in integrity or introduce air bubbles from poor technique into the pores of 
the filter under the monolayer. This isolated the monolayer from the receiver compartment, thereby 
decreasing mass transport noticeably. A broken monolayer exhibited a decrease in its TEER value, but 
air bubbles increase the electrical resistance across the monolayer artificially elevating the subsequent 
TEER values. The 500 µl of sample was initially taken to provide sufficient material for extraction and 
analysis of each drug but caused serious problems with the monolayer. Therefore, analytical 
procedures were developed to reduce the amount of sample required for analysis down to 20 µl while 
maintaining analytical sensitivity. Hence it became possible to reduce the sample volume taken on 
each time point to 50 µl, this provided sufficient sample for analysis and additional volume for 
unforeseen analytical problems. The reduced sample volume decreased the chances that air could get 
under the well insert and decreased the hydrostatic pressure seen with the 50 % liquid replacement 
technique. 
Verification of Transport with Gefitinib and Erlotinib 
The transport of gefitinib across the transwell system without a monolayer established a baseline 
for passive diffusion across the experimental setup. The subsequent sampling procedure dictated the 
calculation methodology; each 15 minute sample dilutes the well concentration by a factor of 0.02. 
Therefore, absolute mass is determined at each time point, adjusted for sample dilution and used as 
the baseline value for each subsequent increase in mass to the next time point. Addition of absolute 
mass transport for each following time point gave the total mass transported. In this way absolute 
mass transported can be determined for all the time points and the Papp calculated. Transport 
decreased significantly when an intact monolayer was used consistent with expectations (Figure 4). 
This could be explained when taking into account the chelation complex being formed in both the 
donor and receiver compartments, reducing the total drug being measured by the highly specific 
LCMSMS technique. 
Comparison of the accumulated mass transport for gefitinib with and without the addition of BSA 
also demonstrated a clear trend (Figure 4). With the addition of BSA a decrease in the relative 
amounts transported across the monolayer was observed (693.8 pmol vs 473.9 pmol, t=3 hr). This 
could be explained by the high protein binding properties of gefitinib which would decrease the 
availability of the drug for transport across the membrane. All remaining experiments were performed 
with medium containing 5 % BSA in both the apical and basolateral compartments. 
 

































With Monolayer + 5% BSA
 
Figure 4. Graphical representation of transport characteristics of Gefitinib (n=4) with and without a monolayer 
across the Transwell setup. Where the medium (HBSS buffer) did not include BSA the total mass transported 
would have been affected by chelation of gefitinib with either calcium or magnesium reducing the measurable 
drug concentrations significantly. Addition of a monolayer to the system slows transport hence total 
accumulated mass while further addition of 5 % BSA also would slow transport lowering the total accumulated 
mass as well. 
 
Model Pharmacokinetic absorption 
Apical to Basolateral (A - B) 
Accumulative mass transport of Gefitinib in the apical to basolateral direction (Figure 5) showed a 
clear linear increase over the time period measured (Papp of 0.38 ± 0.05 µm/ s). When sodium azide 
(NaN3) was added to the system all ATP dependent transport processes would have been blocked. In 
this situation gefitinib showed decrease in the observed mass transported (Papp of 0.32 ± 0.018 µm/s) 
while an even greater decrease was observed when using the specific ABG2 blocker Ko143 (Papp of 
0.26 ± 0.013). Passive transport mechanisms would not be affected by NaN3 but all active mechanisms 
would, similarly Ko143 would not inhibit passive diffusion but all mechanisms involving the ABCG2 
transporter would be inhibited. Therefore it can be concluded from this evidence that gefitinib 
demonstrated evidence of a partial role for active transport mechanisms that occur alongside more 
passive mechanisms. 
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Apical to Basolateral + Ko143






























Basolateral to Apical + NaN3
Basolateral to Apical + Ko143
Basolateral to Apical
 
Figure 5. Graphical representation of accumulated drug transport in the apical to basolateral (A) and the 
basolateral to apical (B) directions for gefitinib using HBSS medium containing 5 %  BSA. Interference in total 
accumulated transport is demonstrated using Ko143 (ABCG2 inhibitor) and NaN3 (inhibitor of ATP processes). 
 
Erlotinib (Figure 6) demonstrated a similar linear increase over the time period to gefitinib but at  
4 - 4.5 fold higher concentrations (Papp of 1.72 ± 0.08 µm/ s). With the addition of NaN3 erlotinib had 
an increase in mass transported (Papp of 2.06 ± 0.15 µm/ s), however, this was not significantly 
different to the transport flow without NaN3. The limited effect of NaN3 on the transport of Erlotinib 
across the membrane suggested that erlotinib transport is predominantly a passive system. However, 
with the addition of Ko143 a decrease in mass transported was observed that was significantly 
different to the control condition (Papp of 1.23 ± 0.06, p> 0.05). This suggested that an active 
mechanism was involved but was an elimination mechanism on the apical membrane only. 
 
Table 3. Summary of the Papp values in both A-B and B-A directions for erlotinib and gefitinib, with and without 
the inclusion of the inhibitors Ko143 and NaN3.Statistical comparisons were made using paired students t-test (#) 
comparing the Papp A-B to the Papp B-A. Additional comparisons were made (*) between the control and either the 
addition of Ko143 or NaN3 
Gefitinib (n=9) Papp (A-B) Papp (B-A) Efflux Ratio 
Control 0.38 ± 0.05 µm/s 0.39 ± 0.038 µm/s 1.03
#
 
+Ko143 0.26 ± 0.013 µm/s** 0.26 ± 0.012 µm/s** 1.00
#
 
+NaN3 0.32 ± 0.018 µm/s* 0.57 ± 0.14 µm/s** 1.78
##
 
    
Erlotinib (n=12) Papp (A-B) Papp (B-A) Efflux Ratio 
Control 1.72 ± 0.08 µm/s 4.51 ± 0.16 µm/s 2.62
###
 
+Ko143 1.23 ± 0.06 µm/s**   
+NaN3 2.06 ± 0.15 µm/s*   
Where * or 
#
 - Not significant Paired students t-test 
** or 
##
 - significantly different (p>0.05) paired students t-test 
*** or 
###
- Highly significantly different (p>0.01) paired students t-test 
(A) (B) 





































Apical to Basolateral + Ko143
Apical to Basolateral + NaN3
 
Figure 6. Graphical representation of accumulated drug transport in the apical to basolateral and the basolateral 
to apical direction for erlotinib using HBss medium containing 5 % BSA. Interference of the ATP based active 
transport mechanisms is demonstrated using NaN3 and Ko143. 
 
Basolateral to Apical (B - A; +5 %  BSA) 
To correctly interpret the pharmacokinetic properties of these drugs as determined using the 
model in the apical to basolateral direction, transport from the blood or cellular situation back to the 
epithelial side of the membrane was also investigated.  
Gefitinib demonstrated very similar flow characteristics in the B - A (Papp 0.39 ± 0.038 µm/ s) 
direction compared to A – B (Figure 5). However, with the addition of NaN3 the flow of gefitinib 
increased significantly (Papp – 0.57 ± 0.14 µm/ s, p > 0.05), whereas with the addition of Ko143 the flow 
decreased significantly (Papp – 0.26 ± 0.012 µm/s, p>0.05). The net efflux ratio of gefitinib was 
determined to be less than 2 (1.0) which indicates a predominate flow in the basolateral to apical 
direction. With the introduction of NaN3 the efflux ratio decreased (0.46) indicating a significant role 
of several active ATP transport mechanisms on both the apical and basolateral membranes in the 
uptake of gefitinib. 
For erlotinib the B - A transport was significantly greater in comparison to A - B (Papp – 4.51 ± 0.16 
µm/ s vs Papp – 1.72 ± 0.08 µm/ s, p > 0.009) indicating a very strong apical efflux flow as suggested by 
the data for the apical to basolateral flow. 
Cellular accumulation of Erlotinib and Gefitinib 
Analysis of cellular accumulation for each drug was performed in the cell pellet after completion of 
the transport studies experiment (Table 4). The accumulation of gefitinib was consistent for both A-B 
and B-A transport mechanisms observed during the Transwell investigation. For A-B transport gefitinib 
accumulation was 792.3 pmol/ mg protein which was lower than the accumulation seen for B-A 
transport (2059.0 pmol/ mg protein) indicating either a decreased uptake via the basolateral layer 
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compared to the apical or a decreased efflux via the apical layer compared to the basolateral. Addition 
of NaN3 to the A-B donor compartment during transport slightly reduced cellular accumulation 
(22.9 %); while the addition of Ko143 had a more significant lowering effect (45.5 %). For B-A 
transport addition of NaN3 led to a similar decrease in accumulation (28 %) but Ko143 had a 
significantly lower difference in accumulation (17.8 %). These results indicate that the measured Papp 
for gefitinib transport is due to a combination of both passive and multiple active processes located 
on differing membranes.  
 
Table 4. The cellular accumulation of gefitinib and erlotinib. Concentration of drug was determined in the 
recovered cells of the monolayer at the end of the transwell experiment (180 min). 
 
Gefitinib  
(pmol / mg protein) 
Erlotinib 
(pmol / mg protein) 
 A – B B – A A – B B - A 
Control (20 µM) 792.3 ± 178.8 2059 ± 256.5 741.1 ± 88.8 674.6 ± 71.6 
20 µM + Ko143 431.7 ± 165.7 1692 ± 242.6 451.6 ± 81.7 
No Data 
20 µM + NaN3 611.3 ± 106.2 1475 ± 156.9 835.8 ± 44.2 
 
Erlotinib demonstrated a similar accumulation in both A-B and B-A directions without addition of 
any inhibitors. With the addition of NaN3 to the apical compartment during A-B transport an increase 
in cellular accumulation is seen (12.8 %), in contrast the addition of Ko143 reduced the cellular 
accumulation similar to that of gefitinib (39.1 %). 
Discussion 
In this paper we described the optimization and validation of a Caco-2 gut epithelial model system 
in order to simulate uptake characteristics of the family of compounds classified under the name of 
Tyrosine Kinase inhibitors. This series of small molecule inhibitors have demonstrated strong in vitro 
chemotherapy potential but many exhibit limited to no clinical effect [27]. The phase 2 and phase 3 
trial failure rates for these compounds is very high with regard to solid tumours. TKIs are referred to 
as “targeted chemotherapy” drugs but have been shown to actually inhibiting a broad range of targets 
which can lead to toxicity and tumour resistance [27]. However, lack of target specificity does not 
completely explain the lack of clinical efficacy. Hence we developed an adaptable model system to 
investigate the pharmacokinetic uptake of these molecules; we used the registered compounds 
gefitinib and erlotinib to validate the models applicability [28]. 
The first major point of the Caco-2 model system is the time in which the monolayers need to be 
prepared, traditionally this has been a time consuming 21 days. To shorten this we utilized a 
commercial system from BD Biosciences that required only a 3 day growth period. Monolayers using 
this system have been shown to have characteristics identical to those grown over 21 days [24]. Initial 
testing demonstrated several problems using this system for the investigation of gefitinib or erlotinib. 
It was observed that the donor compartment concentrations were not stable during the course of the 
experiment showing decreases of 60 % or more of the total drug added to the culture medium. 
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Investigation into this phenomenon indicated that this was due to the buffer matrix used 




 salts and no degradation of the compounds 
could be observed. Mass spectral analysis of Gefitinib and Erlotinib incubated at 37°C in HBSS buffer 
suggested that instead a chelation effect was the cause of the loss of concentration. Yamashita et al 
reported that the relative importance of considering the “physiological conditions of the in vivo drug 
absorption when optimizing the in vitro experimental conditions”. The reference reports that the 
addition of BSA to the medium improved the transport of high lipophilic drugs with poor medium 
solubility across the caco-2 monolayer [29]. Both gefitinib and erlotinib are poorly soluble in aqueous 
solutions and are very highly bound to proteins when circulating in the human system, hence by the 
simple addition of 5 %  BSA we could more closely mimic the “real situation”. More importantly 5 %  
BSA in the medium stabilized the drugs while in solution by preventing “chelation” with the 
magnesium or calcium ions. This, in turn, yielded more reproducible and accurate permeability 
characteristics. It should be noted that the addition of transport inhibitors to this protocol did not 
affect the concentrations of compounds in the initial matrix or after the 3 hour experimental time. 
The next issue we observed was due to the sampling technique at individual time points whereby 
the physical removal of too much of the receiver compartments medium during the experiment led to 
problems with the monolayer where either a rapid increase or a sharp decline in accumulated 
transport could be observed on a random basis. The monolayer could not be observed physically but it 
was reasoned that the observed results were due to either stress breaks or “bubbling effects”. The 
bubbling effect was where air bubbles from sampling procedures had become trapped under the 
monolayer, isolating the donor compartment from the receiver compartment. This had the 
consequence of having very high variation between experimental duplicates and inconsistent results 
on an intra-day basis. Lowering the volume sampled and very careful mixing of a compartment 
contents reduced this issue down to acceptable parameters. However, sample volume was reduced 
from 500 µl to 50 µl, requiring the adaptation of the LCMS analytical techniques to be able to utilize 
only 10-20 µl of sample volume. For gefitinib and erlotinib this proved to be possible. 
With experimental parameters optimized a further problem was identified in that the monolayers 
did not grow consistently across the 24 well plates. Wells in the centre portion of the plate were 
observed to reach starting experimental conditions much slower than those located on the outer rim 
of the plate. This created the condition where centrally placed monolayers were just within 
specifications while outer monolayers were at the maximum limit. This created significant variation in 
the observed transport characteristics. This issue was solved by isolating each well with a breathable 
membrane during the entire growth and experimental periods. The resulting protocol was 
subsequently used to assess transport characteristics of both gefitinib and erlotinib.  
Initial investigations demonstrated significant differences in the transport characteristics between 
gefitinib and erlotinib. Gefitinib demonstrated a 4 fold lower uptake compared to erlotinib when 
considering the transport in the apical to basolateral direction. However, in the reverse direction 
erlotinib demonstrated a significantly higher flow whereas for gefitinib it was similar to the apical to 
basolateral flow. The high flow of erlotinib indicated a potentially large negative flow from the system 
which would lower its overall bioavailability. To test the applicability of the model system further two 
active transport inhibitors were used in combination with gefitinib and erlotinib.  
Active transport systems dependent on ATP would have been blocked and any difference in 
transport behaviour would indicate an active transport mechanism for these compounds. The 
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compound sodium azide inhibits all ATP dependent processes [30]; therefore, if an ATP dependent 
transporter is involved the total amount accumulated would alter depending on which membrane it 
was located on and the direction of flow. This model system demonstrated consistent differences 
between control and inhibited situations indicating that both multiple active and passive transport 
mechanisms are involved in the uptake of both these compounds. These results also indicate that the 
polarized membranes of Caco-2 cells had different mechanisms for both uptake and efflux which were 
different for both compounds. The other inhibitor used was Ko143, a more specific inhibitor of ABCG2 
only [31]. This inhibitor also showed differences for both drugs and between apical or basolateral 
membranes. 
For gefitinib, the presence of NaN3 decreased the observed mass transport in the apical to 
basolateral direction but not completely. This indicated that gefitinib is apparently partially 
transported by both an active transport mechanism and partly by passive diffusion [7]. Inhibition of 
ABCG2 seemed to block the drug from accumulating within the cell suggesting that ABCG2 might be 
one of several transporters involved. However, NaN3 inhibition in the basolateral to apical direction 
increased gefitinib transported whereas Ko143 decreased the total suggesting the role of another 
uncharacterized transporter in addition to ABCG2. 
Investigation into characteristics of erlotinib demonstrated a different apical to basolateral pattern. 
Here NaN3 increased slightly the amount transported while Ko143 decreased the total similar to 
gefitinib in the basolateral to apical directions. However, the total erlotinib transported was 
significantly higher than gefitinib despite the same starting concentration being used. For erlotinib 
significantly lower drug accumulation in the cell was detected suggesting that equilibrium between 
donor and receiver compartments was the driving force of this mechanism with the cellular 
membrane having little resistance to passive diffusion; it should be considered whether the 
paracellular route is possibly the predominant mechanisn involved for this compound. Theoretically 
passive diffusion results in the equilibrium of the compounds between donor, cellular and receiver 
compartments [32]. However, for erlotinib the most significant of the observed effects is that this 
concentration gradient is higher in the basolateral (blood) to apical (gut) direction. This could have 
significant consequences when considered clinically; these results suggest that high single dose 
schedules would have a better bioavailability compared to regular but lower dosing. 
In conclusion we validated a gut epithelial model system to study the potential gut uptake 
mechanisms for two widely used TKIs, erlotinib and gefitinib. The Caco-2 cell monolayer transwell 
system with a 3-day culture system proved to be very adaptable to study drug transport and will be 
very useful to investigating the role of drug transporters using a blocker like probenecid (blocker of 
ABCC) and verapamil (blocker of ABCB1), that would contribute important overview of drug 
transporters involved in transport of TKIs. 
 
Conclusions 
In conclusion we validated a gut epithelial model system to study the potential gut uptake 
mechanisms for two widely used TKIs, erlotinib and gefitinib. The Caco-2 cell monolayer transwell 
system with a 3-day culture system proved to be very adaptable to study drug transport and will be 
very useful to investigating the role of drug transporters using a blocker like probenecid (blocker of 
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ABCC) and verapamil (blocker of ABCB1), that would contribute important overview of drug 
transporters involved in transport of TKIs. 
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